Nothing Special   »   [go: up one dir, main page]

PT3628334T - Gene therapy for retinitis pigmentosa - Google Patents

Gene therapy for retinitis pigmentosa

Info

Publication number
PT3628334T
PT3628334T PT191869296T PT19186929T PT3628334T PT 3628334 T PT3628334 T PT 3628334T PT 191869296 T PT191869296 T PT 191869296T PT 19186929 T PT19186929 T PT 19186929T PT 3628334 T PT3628334 T PT 3628334T
Authority
PT
Portugal
Prior art keywords
gene therapy
retinitis pigmentosa
pigmentosa
retinitis
therapy
Prior art date
Application number
PT191869296T
Other languages
Portuguese (pt)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3628334(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PT3628334T publication Critical patent/PT3628334T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT191869296T 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa PT3628334T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969027P 2014-03-21 2014-03-21

Publications (1)

Publication Number Publication Date
PT3628334T true PT3628334T (en) 2023-09-26

Family

ID=52829343

Family Applications (2)

Application Number Title Priority Date Filing Date
PT191869296T PT3628334T (en) 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa
PT157162322T PT3119437T (en) 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT157162322T PT3119437T (en) 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa

Country Status (36)

Country Link
US (3) US10383953B2 (en)
EP (3) EP4345165A3 (en)
JP (3) JP6669664B2 (en)
KR (2) KR20160127832A (en)
CN (2) CN106456660B (en)
AR (1) AR099837A1 (en)
AU (2) AU2015230942B2 (en)
CA (1) CA2943185A1 (en)
CL (1) CL2016002333A1 (en)
CR (1) CR20160480A (en)
DK (2) DK3628334T5 (en)
DO (1) DOP2016000237A (en)
EA (1) EA201691891A1 (en)
EC (1) ECSP16083000A (en)
ES (2) ES2760263T3 (en)
FI (1) FI3628334T3 (en)
HR (2) HRP20231077T1 (en)
HU (2) HUE063460T2 (en)
IL (3) IL247543B (en)
LT (2) LT3628334T (en)
MA (1) MA39390B2 (en)
MX (2) MX2016012201A (en)
MY (1) MY190726A (en)
NZ (1) NZ724622A (en)
PE (1) PE20161252A1 (en)
PH (1) PH12016501684A1 (en)
PL (2) PL3628334T3 (en)
PT (2) PT3628334T (en)
RS (2) RS59634B1 (en)
SG (3) SG10201912968WA (en)
SI (2) SI3119437T1 (en)
TW (2) TWI780401B (en)
UA (1) UA120050C2 (en)
UY (1) UY36044A (en)
WO (1) WO2015143418A2 (en)
ZA (1) ZA201605924B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3628334T (en) * 2014-03-21 2023-09-26 Genzyme Corp Gene therapy for retinitis pigmentosa
CN107438671B (en) 2015-02-10 2021-05-25 建新公司 Variant RNAi
CN108472390B (en) 2015-12-03 2022-04-15 弗里德里克·米谢尔生物医学研究所 Synp162 promoter for specific expression of gene in rod photoreceptors
US10994026B2 (en) 2015-12-03 2021-05-04 Friedrich Miescher Institute For Biomedical Research SynP160, a promoter for the specific expression of genes in rod photoreceptors
ES2872798T3 (en) * 2015-12-04 2021-11-02 Univ Sorbonne Promoters and uses thereof
WO2017151823A1 (en) * 2016-03-01 2017-09-08 University Of Florida Research Foundation, Inc. Aav vectors for treatment of dominant retinitis pigmentosa
JP2019520391A (en) * 2016-07-05 2019-07-18 ザ・ジョンズ・ホプキンス・ユニバーシティー CRISPR / CAS 9 Based Compositions and Methods for Treating Retinal Degeneration
CN111050805A (en) * 2017-03-21 2020-04-21 斯蒂利亚诺斯·米夏拉克基斯 Gene therapy for treating CNGB 1-related retinitis pigmentosa
US11603529B2 (en) * 2017-09-22 2023-03-14 Genzyme Corporation Variant RNAi
CN111372612A (en) * 2017-09-27 2020-07-03 西吉隆医疗股份有限公司 Methods, compositions, and implantable elements comprising viable cells
CN107961380B (en) * 2017-11-23 2020-05-05 清华大学 Use of reagent in preparation of medicine, method for screening medicine and medicine composition
WO2019183630A2 (en) * 2018-03-23 2019-09-26 The Trustees Of Columbia University In The City Of New York Gene editing for autosomal dominant diseases
CN112204145B (en) * 2018-06-01 2024-03-26 佛罗里达大学研究基金会有限公司 Compositions and methods for treating dominant retinitis pigmentosa
GB201817469D0 (en) * 2018-10-26 2018-12-12 Univ Oxford Innovation Ltd Gene therapy for retinal disease
CN111518813B (en) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 Coding sequence of rhodopsin, construction of expression vector and application thereof
KR20210141945A (en) * 2019-03-04 2021-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Neuroprotective gene therapy targeting the AKT pathway
EA202192543A1 (en) * 2019-03-21 2021-12-27 Птс Терапьютикс, Инк. VECTOR AND METHOD FOR TREATMENT OF ANGELMAN'S SYNDROME
CN114521214A (en) * 2020-07-24 2022-05-20 尔知渃米斯股份有限公司 Rhodopsin transcript-specific trans-splicing ribozyme and application thereof
TWI832531B (en) * 2022-11-02 2024-02-11 慈濟學校財團法人慈濟大學 Use of a rip1 inhibitor or a mlkl inhibitor for treating or preventing hereditary retinal dystrophy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP2369002A1 (en) 1999-08-09 2011-09-28 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
WO2001092551A2 (en) 2000-06-01 2001-12-06 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
ES2455126T3 (en) 2001-11-13 2014-04-14 The Trustees Of The University Of Pennsylvania Cy.5 sequences of adeno-associated virus (AAV), vectors that contain them and their use.
CA2553976C (en) * 2004-01-22 2013-09-24 Dnavec Research Inc. Method for producing minus-strand rna viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken .beta.-actin promoter
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
WO2008125846A2 (en) * 2007-04-12 2008-10-23 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Genetic suppression and replacement
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
CA2773619C (en) * 2009-09-10 2019-11-12 Svend Lindenberg Method for the preparation of micro-rna and its therapeutic application
EP2529020B1 (en) 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US10738326B2 (en) * 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
SG192268A1 (en) 2011-02-17 2013-08-30 Univ Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
JP5884152B2 (en) 2011-07-29 2016-03-15 シャープ株式会社 Base station, terminal, communication system and communication method
ITRM20110685A1 (en) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And MICRORNA FOR CARDIAC REGENERATION THROUGH THE INDUCTION OF THE PROLIFERATION OF CARDIAC MYCYCLES
SG11201404956PA (en) * 2012-02-17 2014-09-26 Philadelphia Children Hospital Aav vector compositions and methods for gene transfer to cells, organs and tissues
CA2868996A1 (en) * 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
ES2636902T3 (en) 2012-05-25 2017-10-10 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modulation
JP6199965B2 (en) * 2012-07-11 2017-09-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア AAV-mediated gene therapy for RPGRX-linked retinal degeneration
WO2014066498A1 (en) * 2012-10-23 2014-05-01 Vivek Mittal Treatment of metastatic breast cancer
TW201605470A (en) 2013-10-04 2016-02-16 默沙東藥廠 Glucose-responsive insulin conjugates
PT3628334T (en) 2014-03-21 2023-09-26 Genzyme Corp Gene therapy for retinitis pigmentosa

Also Published As

Publication number Publication date
HUE063460T2 (en) 2024-01-28
IL284741B (en) 2022-10-01
CR20160480A (en) 2016-12-14
FI3628334T3 (en) 2023-09-15
LT3119437T (en) 2019-12-27
EP4345165A2 (en) 2024-04-03
TWI780401B (en) 2022-10-11
US20200046851A1 (en) 2020-02-13
BR112016021017A2 (en) 2017-10-03
JP7534348B2 (en) 2024-08-14
KR20230006039A (en) 2023-01-10
DOP2016000237A (en) 2016-10-16
AU2015230942A1 (en) 2016-10-13
AR099837A1 (en) 2016-08-24
EP4345165A3 (en) 2024-09-25
HUE046454T2 (en) 2020-03-30
UA120050C2 (en) 2019-09-25
SG10201912968WA (en) 2020-02-27
US20170173183A1 (en) 2017-06-22
US10383953B2 (en) 2019-08-20
CN115252823A (en) 2022-11-01
WO2015143418A2 (en) 2015-09-24
EP3119437B1 (en) 2019-09-04
PE20161252A1 (en) 2016-11-30
UY36044A (en) 2015-10-30
PH12016501684A1 (en) 2016-10-03
TWI706789B (en) 2020-10-11
RS59634B1 (en) 2020-01-31
HRP20192141T1 (en) 2020-02-21
MA39390A1 (en) 2017-12-29
PL3119437T3 (en) 2020-04-30
MY190726A (en) 2022-05-12
US20220054657A1 (en) 2022-02-24
TW201622752A (en) 2016-07-01
DK3119437T3 (en) 2019-12-09
CA2943185A1 (en) 2015-09-24
IL247543B (en) 2020-07-30
MX2016012201A (en) 2017-01-19
DK3628334T3 (en) 2023-10-02
DK3628334T5 (en) 2024-09-02
JP2017509632A (en) 2017-04-06
AU2015230942B2 (en) 2020-11-19
MA39390B2 (en) 2022-04-29
EA201691891A1 (en) 2017-01-30
IL275918B (en) 2021-07-29
ES2760263T3 (en) 2020-05-13
EP3628334B1 (en) 2023-06-28
CL2016002333A1 (en) 2017-05-26
NZ724622A (en) 2022-05-27
CN106456660B (en) 2022-05-31
IL247543A0 (en) 2016-11-30
AU2021200988A1 (en) 2021-03-11
LT3628334T (en) 2023-09-25
JP2020059737A (en) 2020-04-16
RS64611B1 (en) 2023-10-31
HRP20231077T1 (en) 2023-12-22
SI3119437T1 (en) 2020-01-31
IL284741B2 (en) 2023-02-01
JP2022084810A (en) 2022-06-07
MX2020010694A (en) 2020-11-06
JP7048563B2 (en) 2022-04-05
IL275918A (en) 2020-08-31
CN106456660A (en) 2017-02-22
US11103598B2 (en) 2021-08-31
NZ762841A (en) 2023-11-24
ECSP16083000A (en) 2017-02-24
ES2957840T3 (en) 2024-01-26
EP3119437A2 (en) 2017-01-25
WO2015143418A3 (en) 2015-11-19
SG11201607005UA (en) 2016-09-29
SI3628334T1 (en) 2023-11-30
TW202021627A (en) 2020-06-16
IL284741A (en) 2021-08-31
PL3628334T3 (en) 2023-12-18
KR20160127832A (en) 2016-11-04
ZA201605924B (en) 2017-09-27
AU2021200988B2 (en) 2024-08-01
EP3628334A1 (en) 2020-04-01
SG10201808218YA (en) 2018-10-30
JP6669664B2 (en) 2020-03-18
PT3119437T (en) 2019-12-12

Similar Documents

Publication Publication Date Title
IL284741A (en) Gene therapy for retinitis pigmentosa
IL284577A (en) Gene therapy
HK1250727A1 (en) Treatment of retinitis pigmentosa
PT3191139T (en) Rpgr gene therapy for retinitis pigmentosa
GB201407322D0 (en) Gene therapy
GB201707212D0 (en) Gene therapy for ciliopathies
IL263085A (en) Gene therapy
GB201616821D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy